复方苦参注射液联合小剂量5-氟尿嘧啶对胃癌SGC-7901细胞血管内皮生长因子及趋化因子受体表达的影响  

Effect of matrine injection combined with low dosage of 5-Fu on expressions of VEGF and CXCR4 in gastric carcer SGC 7901 cells

作　　者：杨勤[1] 张亚声[1] 

机构地区：[1]上海交通大学附属第一人民医院中医科,上海200080

出　　处：《中国中西医结合消化杂志》2010年第3期172-176,共5页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

摘　　要：[目的]探讨复方苦参注射液(MI)联合小剂量5-氟尿嘧啶(5-Fu)对人胃癌SGC-7901细胞中血管内皮生长因子(VEGF)、趋化因子受体(CXCR4)mRNA及蛋白表达的影响。[方法]采用溴化噻唑蓝四氮唑法观察MI联合小剂量5-Fu对人胃癌SGC-7901细胞增殖的影响;采用逆转录聚合酶链反应法、免疫荧光法、酶联免疫吸附法分别检测MI联合小剂量5-Fu对人胃癌SGC-7901细胞中VEGF、CXCR4 mRNA及蛋白表达水平。[结果]单独应用40μl/ml MI或小剂量(20μg/ml)5-Fu作用于SGC-7901细胞后,与对照组比较,两者均能抑制细胞增殖;20μg/ml5-Fu对VEGF、CXCR4 mRNA水平无明显影响(P>0.05),40μl/ml MI减少VEGF、CXCR4 mRNA及蛋白表达水平(P<0.05);两者联用后能明显降低SGC-7901细胞VEGF、CXCR4 mRNA及蛋白表达水平(P<0.01)。[结论]MI联合小剂量5-Fu具有明显的抑制肿瘤血管生成因子的作用,这可能是MI抗肿瘤血管生成的机制之一。[Objective]To investigate effect of matrine injection（MI）combined with low dosage of 5-Fu on expressions of vascular endothelial growth factor（VEGF）and CXC chemokine receptor 4（CXCR4）of gastric carcinoma SGC 7901 cells.[Methods]Methyl thiazolyl tetrazolium assay（MTT）was used to evaluate the effect of MI combined with low dosage of 5-Fu on proliferation of SGC 7901 cells;Reverse transcription polymerase chain reaction（RT-PCR）,immunofluorescenceand enzyme linked immunosorbent assay（ELISA）were employed to measure expressions of mRNAs and proteins of VEGF and CXCR4 in gastric carcinoma SGC 7901 cells respectively.[Results]MI（40 μl/ml）or 5-Fu（20 μg/ml）,could both inhibit the proliferation of SGC-7901 cells.MI（40 μl/ml）could reduce the expressions of VEGF and CXCR4 in SGC 7901 cells（P0.05）.5-Fu（20 μg/ml）had no significant effect on expression of mRNA of VEGF and CXCR4（P0.05）Expressions decreased significantly in the combined group versus the control group（P0.01）.[Conclusion]MI combined with low dosage of 5-Fu can markedly inhibit the expressions of VEGF in carcinoma which may be one of anti-angiogenic mechanisms of MI.

关 键 词：胃肿瘤 复方苦参注射液 5-氟尿嘧啶 胃癌SGC-7901细胞 血管内皮生长因子 趋化因子受体 

分 类 号：R735.2[医药卫生—肿瘤] R281.71[医药卫生—临床医学]